A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Co-administration of oral killed whole-cell recombinant cholera toxin B-subunit vaccine (WC-rCTB) and live Salmonella Typhi Ty21a vaccine: a prospective randomized open-label trial




TekijätRiekkinen, Marianna; Terrinoni, Manuela; Pakkanen, Sari H.; Kaim, Joanna; Vahlberg, Tero; Lundgren, Anna; Kantele, Anu

KustantajaOxford University Press

Julkaisuvuosi2026

Lehti: Journal of Travel Medicine

Vuosikerta33

Numero2

ISSN1195-1982

eISSN1708-8305

DOIhttps://doi.org/10.1093/jtm/taag008

Julkaisun avoimuus kirjaamishetkelläAvoimesti saatavilla

Julkaisukanavan avoimuus Osittain avoin julkaisukanava

Verkko-osoitehttps://academic.oup.com/jtm/article/33/2/taag008/8464194

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/515904657

Rinnakkaistallenteen lisenssiCC BY

Rinnakkaistallennetun julkaisun versioKustantajan versio


Tiivistelmä

Background

Cholera and typhoid fever are often co-endemic, making vaccine co-administration practical. However, due to lack of immunogenicity data, current guidelines advise against co-administration of the oral inactivated whole-cell recombinant cholera toxin B-subunit vaccine (WC-rCTB) and the oral live Salmonella Typhi Ty21a vaccine.

Methods

Healthy adults (18–65 years) were randomized 1:1:1 to receive WC-rCTB with Ty21a (group Ch + Ty), WC-rCTB alone (group Ch) or Ty21a alone (group Ty). Peripheral blood mononuclear cells (PBMCs) were isolated on Days 0, 5 and 7 from all, plus on Days 12 and 14 from WC-rCTB recipients, to assess antibody-secreting cells (ASCs) specific to rCTB and to typhoidal O9,12-structures by enzyme-linked immunosorbent spot (ELISPOT) assay. Vibriocidal antibodies were assessed, and anti-rCTB IgA/IgG and anti-S. Typhi lipopolysaccharide (LPS) IgA/IgG/IgM were measured by enzyme-linked immunosorbent assay (ELISA) in Day 0 and 28 ± 3 serum samples. Adverse events (AEs) were recorded during one month.

Results

The final study population included 63 volunteers, 21 per group. A non-significant trend towards stronger rCTB-specific ASC (IgA + IgG + IgM) peak responses was observed in group Ch + Ty compared to group Ch (geometric mean, GM 94 vs 32 ASC/106 PBMC, P = 0.096). Serum anti-rCTB IgA and IgG fold rises (post-vaccination vs pre-vaccination) were higher in group Ch + Ty than in group Ch (IgA P = 0.039, IgG P = 0.028), whereas vibriocidal fold rises were comparable between the two groups (P = 0.847). ASC (IgA + IgG + IgM) peak responses to typhoidal O9,12-structures were comparable between groups Ch + Ty and Ty (GM 183 vs. 210 ASC/106 PBMC, P = 0.684). Serum anti-S. Typhi LPS IgA, IgG and IgM fold rises were also similar across Ch + Ty and Ty groups (all P-values ≥0.145). AEs were comparable in single and co-administration groups.

Conclusions

Co-administration of the oral cholera and typhoid vaccines demonstrated favourable safety and robust immunogenicity for both vaccines, supporting their simultaneous use without spacing precautions.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
This work was supported by an investigator-initiated grant from Valneva [20268, A.K.]; the Finnish Governmental Subsidy for Health Science Research [A.K.]; the University of Helsinki Doctoral School [M.R.]; the Inflammation Center of HUS, Helsinki University Hospital [M.R.]; and the Finnish Medical Foundation [9387, M.R.]. The funders had no role in design or conduct of the study or writing of the manuscript.


Last updated on